Gian Paolo Dagrada

List of Publications by Year
in descending order

59 papers	3,297 citations	147566 31 h-index	149479 56 g-index
60 all docs	60 docs citations	60 times ranked	4385 citing authors

#	Article	IF	Citations
1	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 2010, 116, e56-e65.	0.6	315
2	A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia, 2012, 26, 349-355.	3.3	298
3	Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. Clinical Cancer Research, 2006, 12, 6643-6651.	3.2	159
4	Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. Clinical Cancer Research, 2011, 17, 7776-7784.	3.2	147
5	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia, 2006, 20, 1610-1617.	3.3	141
6	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. Clinical Cancer Research, 2006, 12, 6920-6928.	3.2	135
7	Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood, 2007, 110, 3291-3300.	0.6	133
8	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptorâ€“positive salivary gland cancers. Head and Neck, 2016, 38, 724-731.	0.9	104
9	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. American Journal of Surgical Pathology, 2015, 39, 383-393.	2.1	101
10	Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications. Clinical Cancer Research, 2008, 14, 6033-6041.	3.2	88
11	The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica, 2010, 95, 1221-1225.	1.7	84
12	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). Clinical Cancer Research, 2016, 22, 837-846.	3.2	78
13	Activity of sunitinib in extraskeletal myxoid chondrosarcoma. European Journal of Cancer, 2014, 50, 1657-1664.	1.3	74
14	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica, 2009, 94, 1708-1713.	1.7	68
15	Molecular cytogenetic characterization of proximal-type epithelioid sarcoma. Genes Chromosomes and Cancer, 2004, 41, 283-290.	1.5	67
16	Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. Modern Pathology, 2015, 28, 1074-1083.	2.9	67
17	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. European Journal of Cancer, 2016, 69, 158-165.	1.3	66
18	Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes and Cancer, 2009, 48, 624-636.	1.5	65

#	Article	IF	Citations
19	The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomideâ€based therapy. Genes Chromosomes and Cancer, 2011, 50, 765-774.	1.5	59
20	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 1252-1262.	5.1	57
21	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized forc-kit and platelet-derived growth factor receptor Î± gene alterations. Cancer, 2005, 104, 159-169.	2.0	56
22	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. Annals of Surgical Oncology, 2016, 23, 2735-2744.	0.7	56
23	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. European Journal of Cancer, 2014, 50, 3021-3028.	1.3	50
24	PDGFRÎ±, PDGFRÎ² and KIT expression/activation in conventional chondrosarcoma. Journal of Pathology, 2006, 208, 615-623.	2.1	48
25	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. Haematologica, 2009, 94, 1024-1028.	1.7	47
26	Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. Oncotarget, 2016, 7, 47848-47863.	0.8	43
27	Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1703-1707.	1.1	39
28	<scp>HSPA</scp>8 as a novel fusion partner of <scp>NR</scp>4<scp>A</scp>3 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes and Cancer, 2017, 56, 582-586.	1.5	38
29	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. Frontiers in Oncology, 2020, 10, 489.	1.3	38
30	Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology, 2004, 44, 301-302.	1.6	34
31	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clinical Sarcoma Research, 2013, 3, 16.	2.3	34
32	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. European Journal of Cancer, 2019, 106, 225-233.	1.3	32
33	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. Journal of Investigative Dermatology, 2017, 137, 484-493.	0.3	29
34	Evidence of Neural Differentiation in a Case of Post-therapy Primitive Neuroectodermal Tumor/Ewing Sarcoma of Bone. American Journal of Surgical Pathology, 2003, 27, 1161-1166.	2.1	27
35	Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. Clinical Sarcoma Research, 2012, 2, 22.	2.3	27
36	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. Journal of Pathology, 2019, 249, 90-101.	2.1	27

#	Article	IF	Citations
37	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. European Journal of Cancer, 2017, 76, 84-92.	1.3	26
38	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelialâ€“Mesenchymal Transitionâ€“like Process and 22q Loss. Molecular Cancer Research, 2016, 14, 820-829.	1.5	25
39	The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelialâ€“mesenchymal transition, and immune response. Cancer Communications, 2018, 38, 1-14.	3.7	25
40	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A caseâ€series analysis within the Italian Rare Cancer Network. Cancer, 2021, 127, 569-576.	2.0	24
41	HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing. Breast Cancer Research and Treatment, 2003, 80, 207-214.	1.1	23
42	HerceptinÂ® plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncology, 2005, 41, 97-98.	0.8	23
43	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. British Journal of Cancer, 2014, 111, 1350-1362.	2.9	21
44	The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with MDM2 and CDK4 amplification. Histopathology, 2021, 78, 290-299.	1.6	21
45	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget, 2017, 8, 60036-60045.	0.8	17
46	Opposite deletions/duplications of the X chromosome: two novel reciprocal rearrangements. European Journal of Human Genetics, 2000, 8, 63-70.	1.4	16
47	Immunophenotypic and genotypic analysis of a case of primary peripheral primitive neuroectodermal tumour (pPNET) of the urinary bladder. Histopathology, 2002, 40, 108-109.	1.6	16
48	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. Oncotarget, 2016, 7, 75503-75517.	0.8	16
49	TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Translational Oncology, 2008, 1, 121-128.	1.7	15
50	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. Modern Pathology, 2020, 33, 217-227.	2.9	15
51	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. Neuro-Oncology, 2014, 16, 72-80.	0.6	13
52	Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma. Journal of Clinical Oncology, 2011, 29, e37-e39.	0.8	12
53	Mechanism of action of trabectedin in desmoplastic small round cell tumor cells. BMC Cancer, 2017, 17, 107.	1.1	11
54	Self-Assembled Nanomicelles as Curcumin Drug Delivery Vehicles: Impact on Solitary Fibrous Tumor Cell Protein Expression and Viability. Molecular Pharmaceutics, 2018, 15, 4689-4701.	2.3	11

#	Article	IF	Citations
55	Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). Pediatric Blood and Cancer, 2020, 67, e28351.	0.8	11
56	SYT-SSX Fusion Transcripts and Epithelial Differentiation in Synovial Sarcoma. Diagnostic Molecular Pathology, 2000, 9, 234.	2.1	8
57	Detection of bladder cancer by multitarget multicolour FISH: comparative analysis on archival cytology and paraffin-embedded tissue. Cytopathology, 2002, 13, 317-325.	0.4	7
58	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. International Journal of Molecular Sciences, 2018, 19, 1855.	1.8	4
59	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. Oral Oncology, 2016, 58, e4-e5.	0.8	3